3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Colorectal Neoplasms
26
Rectal Neoplasms
6
Colonic Neoplasms
6
Neoplasm Metastasis
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Advanced Solid Tumors
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Gallbladder Neoplasms
2
Advanced Solid Tumors (Excluding Breast Cancer)
2
Urologic Diseases
1
Solid Tumor Cancer
1
Renal Insufficiency
1
Refractory Solid Tumors
1
Pretreated Metastatic Colorectal Cancer
1
Neoplasms
1
Liver Neoplasms
1
Liver Diseases
1
Kidney Neoplasms
1
Kidney Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Gastric Adenocarcinoma
1
Digestive System Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Advanced or Metastatic Solid Tumors
1
Interventions
Carboplatin
27
Paclitaxel
23
Cisplatin
22
Gemcitabine
17
pembrolizumab
15
Fluorouracil
9
Pemetrexed
8
Everolimus
8
Docetaxel
8
Cetuximab
8
Radiotherapy, Intensity-Modulated
7
Radiotherapy
7
130-nm albumin-bound paclitaxel
7
Sorafenib
6
Nivolumab
6
Bevacizumab
6
Axitinib
6
epothilone B
5
Sunitinib
5
Radiation
5
Panitumumab
5
Cyclophosphamide
5
trebananib
4
reolysin
4
padeliporfin
4
lenvatinib
4
Irinotecan
4
Gefitinib
4
vosaroxin
3
volociximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma
×
trifluridine tipiracil drug combination
×
Clear all
NCT02920476
2022-06-23
UF-STO-LUNG-003
University of Florida
Phase 2
Completed
4 enrolled
8 charts